KWA
ADCT icon

Kingswood Wealth Advisors’s ADC Therapeutics ADCT Stock Holding History

Kingswood Wealth Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Buy
105,107
+107
+0.1% +$422 0.02% 623
2025
Q4 		$371K Buy
+105,000
New +$426K 0.02% 616

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kingswood Wealth Advisors's ADCT Position: Q1 2026 in Review

Kingswood Wealth Advisors increased its ADC Therapeutics (ADCT) stake by 0.1% in Q1 2026, buying an estimated $422 and bringing the position to 105,107 shares worth $394K. The position accounts for 0.02% of the portfolio, ranked #623.

Kingswood Wealth Advisors first reported a position in ADCT in Q4 2025 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Kingswood Wealth Advisors held 105,107 shares of ADC Therapeutics worth $394K as of Q1 2026.
  • Kingswood Wealth Advisors bought 107 ADC Therapeutics shares in Q1 2026, an estimated $422.
  • ADC Therapeutics made up 0.02% of Kingswood Wealth Advisors's portfolio in Q1 2026, its #623 holding.
  • Kingswood Wealth Advisors first reported a position in ADC Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.